Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:ARCT OTCMKTS:CSLLY NYSE:NVS On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeARCTArcturus Therapeutics$7.53$7.95$5.85▼$24.17$214.00M2.36344,609 shs466,259 shsCSLLYCSL$19.00$20.20$16.01▼$44.86$36.40B0.61571,722 shs371,663 shsNVSNovartis$147.17+0.1%$149.24$112.34▼$170.46$280.82B0.461.68 million shs1.87 million shs10 Stocks Powering The Next AI Boom The AI boom is creating opportunities across semiconductors, cloud computing, enterprise software, infrastructure, cybersecurity, and automation. Inside this report, you’ll find 10 companies positioned to benefit as artificial intelligence moves from hype to real-world deployment and becomes a core growth driver for corporate America.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceARCTArcturus Therapeutics+2.31%+8.27%+12.56%+13.57%-39.03%CSLLYCSL+3.20%-0.73%+9.32%-20.67%-75.92%NVSNovartis-2.52%-4.41%-2.14%+0.86%+26.90%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeARCTArcturus Therapeutics$7.53$7.95$5.85▼$24.17$214.00M2.36344,609 shs466,259 shsCSLLYCSL$19.00$20.20$16.01▼$44.86$36.40B0.61571,722 shs371,663 shsNVSNovartis$147.17+0.1%$149.24$112.34▼$170.46$280.82B0.461.68 million shs1.87 million shs10 Stocks Powering The Next AI Boom The AI boom is creating opportunities across semiconductors, cloud computing, enterprise software, infrastructure, cybersecurity, and automation. Inside this report, you’ll find 10 companies positioned to benefit as artificial intelligence moves from hype to real-world deployment and becomes a core growth driver for corporate America.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceARCTArcturus Therapeutics+2.31%+8.27%+12.56%+13.57%-39.03%CSLLYCSL+3.20%-0.73%+9.32%-20.67%-75.92%NVSNovartis-2.52%-4.41%-2.14%+0.86%+26.90%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceARCTArcturus Therapeutics 2.67Moderate Buy$25.44237.91% UpsideCSLLYCSL 1.80ReduceN/AN/ANVSNovartis 2.31Hold$141.20-4.06% DownsideCurrent Analyst Ratings BreakdownLatest CSLLY, NVS, and ARCT Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails5/29/2026CSLLYCSL Jefferies Financial GroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeStrong-Buy ➝ Hold5/11/2026CSLLYCSL Canaccord Genuity GroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeStrong-Buy ➝ Hold5/11/2026CSLLYCSL Zacks ResearchSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeHold ➝ Strong Sell5/11/2026CSLLYCSL CitigroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeStrong-Buy ➝ Hold4/29/2026NVSNovartis Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeBuy (A-) ➝ Buy (B)4/21/2026ARCTArcturus Therapeutics Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeSell (E+) ➝ Sell (D-)3/26/2026NVSNovartis Morgan StanleySubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetOverweight$143.00 ➝ $170.003/19/2026NVSNovartis Sanford C. BernsteinSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeHold(Data available from 6/19/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookARCTArcturus Therapeutics$82.03M2.61N/AN/A$7.53 per share1.00CSLLYCSL$15.56B2.34$2.26 per share8.42$11.05 per share1.72NVSNovartis$54.53B5.15$10.47 per share14.05$22.04 per share6.68Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateARCTArcturus Therapeutics-$65.78M-$2.81N/AN/AN/A-143.80%-36.55%-28.40%8/10/2026 (Estimated)CSLLYCSL$3.00BN/AN/A12.10N/AN/AN/AN/AN/ANVSNovartis$13.98B$6.9821.0814.992.6624.87%38.82%15.16%7/21/2026 (Estimated)Latest CSLLY, NVS, and ARCT EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/8/2026Q1 2026ARCTArcturus Therapeutics-$1.0320-$0.95+$0.0820-$0.95$6.30 million$2.06 million4/27/2026Q1 2026NVSNovartis$2.11$1.99-$0.12$1.65$13.44 billion$13.52 billionCompare DividendsCompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive GrowthARCTArcturus TherapeuticsN/AN/AN/AN/AN/ACSLLYCSL$0.593.11%N/AN/AN/ANVSNovartis$3.082.09%+5.28%44.13%N/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioARCTArcturus TherapeuticsN/A6.316.31CSLLYCSL0.512.571.15NVSNovartis0.960.850.65Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipARCTArcturus Therapeutics94.54%CSLLYCSL0.03%NVSNovartis13.12%Insider OwnershipCompanyInsider OwnershipARCTArcturus Therapeutics17.80%CSLLYCSLN/ANVSNovartis0.01%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableARCTArcturus Therapeutics18028.42 million23.36 millionOptionableCSLLYCSL29,9041.92 billionN/ANot OptionableNVSNovartis75,2671.91 billion1.91 billionOptionableCSLLY, NVS, and ARCT HeadlinesRecent News About These CompaniesNovartis' Rhapsido Meets Primary Goal in Phase III Skin Disorder StudyJune 15, 2026 | zacks.comNovartis FY2026 EPS Forecast Increased by Erste Group BankJune 15, 2026 | americanbankingnews.comDividend Safety Check: FNDF and International Large-Cap Dividend IncomeJune 13, 2026 | 247wallst.comNovartis muscle disease therapy succeeds in early-stage studyJune 12, 2026 | msn.comNovartis RemIND data at EAACI show Rhapsido® potential as first targeted therapy for chronic inducible urticaria (CIndU)June 12, 2026 | globenewswire.comKymera, Monte Rosa among gainers as Novartis inks deal for molecular glue drugsJune 11, 2026 | seekingalpha.comNovartis says rare muscle disease drug shows promise in early trialJune 11, 2026 | reuters.comNovartis Reports Positive Data for Neuromuscular Disorder DrugJune 11, 2026 | zacks.comPharma and Biotech M&A Boom Accelerates as Companies Expand PipelinesJune 11, 2026 | zacks.comNovartis' $12 billion bet pays off with encouraging data from rare neuromuscular disease studyJune 11, 2026 | msn.comHealthcare ETFs: From Broad Exposure to Big BreakthroughsJune 11, 2026 | etftrends.comENovartis delpacibart braxlosiran (del-brax) Phase I/II study in facioscapulohumeral muscular dystrophy (FSHD) meets primary biomarker endpointJune 11, 2026 | globenewswire.comBarclays Keeps Their Hold Rating on Novartis AG (NOVN)June 9, 2026 | theglobeandmail.comNovartis to highlight Rhapsido® data across multiple immune-mediated diseases at EAACI Congress 2026June 8, 2026 | globenewswire.comArgus Research Reaffirms Their Buy Rating on Novartis (NVS)June 6, 2026 | theglobeandmail.comNovartis (NVS) Reports New Cosentyx® Data in Polymyalgia RheumaticaJune 5, 2026 | insidermonkey.comBIIB's Next-Gen SMA Therapy Salanersen Wins FDA's Breakthrough TagJune 5, 2026 | zacks.comNovartis IgAN data in The Lancet show clinically meaningful slowing of kidney function decline with Vanrafia® over 2.5 yearsJune 4, 2026 | globenewswire.comNovartis Cosentyx® PMR data in New England Journal of Medicine showed sustained remission vs placebo in twice as many patientsJune 3, 2026 | globenewswire.comNovartis announces results on rPFS improvements across subgroups with PluvictoJune 1, 2026 | finance.yahoo.comAs U.S. Debt Surpasses GDP, These 2 ETFs Are Emerging Winners in the “Sell America” Trade (NVS)...May 18, 2026 | marketbeat.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeCSLLY, NVS, and ARCT Company DescriptionsArcturus Therapeutics NASDAQ:ARCT$7.53 0.00 (0.00%) Closing price 06/18/2026 04:00 PM EasternExtended Trading$7.50 -0.03 (-0.41%) As of 06/18/2026 06:54 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Arcturus Therapeutics Holdings Inc., a late-stage clinical messenger RNA medicines and vaccine company, focuses on the development of infectious disease vaccines and other products within liver and respiratory rare diseases. Its technology platforms include LUNAR lipid-mediated delivery and STARR mRNA. The company is developing ARCT-810 (LUNAR-OTC), a mRNA-based therapeutic candidate, which is in Phase 2 clinical trial for treating ornithine transcarbamylase deficiency; and ARCT-154 (LUNAR-COV19), a mRNA vaccine candidate that is in Phase 3 arm of a Phase 1/2/3 study in Vietnam for the treatment of COVID-19, as well as ARCT-032 (LUNAR-CF), a mRNA therapeutic candidate for cystic fibrosis. Its product pipeline includes, ARCT-2301 for bivalent: ancestral/omicron which is in Phase 3; ARCT-2303 for monovalent that is in Phase 3; ARCT-2138 for quadrivalent which is in Phase 1; and LUNAR-FLU which is in pre-clinical trial. Arcturus Therapeutics Holdings Inc. was founded in 2013 and is headquartered in San Diego, California.CSL OTCMKTS:CSLLY$19.00 0.00 (0.00%) As of 06/18/2026 03:59 PM EasternCSL Limited researches, develops, manufactures, markets, and distributes biopharmaceutical and vaccines in Australia, the United States, Germany, the United Kingdom, Switzerland, China, Hong Kong, and internationally. The company operates through CSL Behring, CSL Seqirus, and CSL Vifor segments. The CSL Behring segment offers plasma products, gene therapies, and recombinants. The CSL Seqirus segment provides influenza related products and pandemic services to governments. The CSL Vifor segment offers products in the therapeutic areas of iron deficiency and nephrology. The company also licenses CSL intellectual property. CSL Limited was founded in 1916 and is headquartered in Melbourne, Australia.Novartis NYSE:NVS$147.17 +0.09 (+0.06%) Closing price 06/18/2026 03:59 PM EasternExtended Trading$147.65 +0.48 (+0.32%) As of 06/18/2026 07:10 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Novartis AG engages in the research, development, manufacture, and marketing of healthcare products in Switzerland and internationally. The company offers prescription medicines for patients and physicians. It focuses on therapeutic areas, such as cardiovascular, renal and metabolic, immunology, neuroscience, and oncology, as well as ophthalmology and hematology. Novartis AG has a license and collaboration agreement with Alnylam Pharmaceuticals to develop, manufacture, and commercialize inclisiran, a therapy to reduce LDL cholesterol; and Dawn Health for the development and commercialization of Ekiva, a digital solution designed for people living with Paroxysmal Nocturnal Hemoglobinuria. The company was incorporated in 1996 and is headquartered in Basel, Switzerland. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSilverSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Satellogic Is Tiny But Its Revenue Growth Is Hard to Ignore Aehr Spikes on New Order, But Has Stock Gotten Ahead of Itself? Why Kroger’s Pullback Could Be a Gift for Patient Investors Credo Technologies Accelerates AI—Its Stock Price Will Follow Why Rocket Lab’s Nasdaq-100 Moment Could Change the Story Why Palantir’s Google Cloud Deal Could Change the Debate VMware: Broadcom's Second Biggest Business Set to Accelerate American Eagle’s Q1 Beat Leaves Investors With a Bigger Question Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
